In fact, A-1331852, a BH3-mimetic with specific anti-BCL-xL-binding capacity [29], is an effective agent to increase regorafenib efficacy and to overcome regorafenib resistance as we will demonstrate in different in vitro and in vivo HCC models. This evidence concerns the gene BCL2L1 and hepatocellular carcinoma.